After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the biologic ...

Argatroban could revive the practice of acute anticoagulation for reducing disability after stroke, based on the EASE trial from China. In patients with acute ischemic stroke and early neurological ...

SPORTIF V, a North American trial, has now reported the same findings. The protocols of SPORTIF III and SPORTIF V were identical, except that SPORTIF III had an open-label design with blinded event ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Direct thrombin inhibitors prevent the conversion of fibrinogen into fibrin during the coagulation cascade and ultimately prevent the development of a thrombus. 11 Dabigatran etexilate was the first ...

Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots. But the most commonly used, heparin, ...

For people with hemophilia, deficiencies in factor VIII (hemophilia A) or factor IX (hemophilia B) lead to insufficient thrombin generation, which can lead to excessive or spontaneous bleeding. 3,7 In ...

If you’re experiencing severe side effects from the blood thinner warfarin, a doctor may recommend an alternative known as non-vitamin K oral anticoagulants (NOACs). Non-vitamin K oral anticoagulants ...

Researchers have developed a system for designing protein inhibitors with reversible activity. The method is based on a supramolecular drug that results from the interaction of two or more molecules ...